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Renal damage can be difficult to assess
clinically. The kidney has excess functional
capacity, and in most cases a signiﬁcant pro-
portion of the kidney must be ablated before
changes in kidney function are observed
(Price 1992). Currently available biomarkers,
such as blood urea nitrogen or serum creati-
nine, are not very sensitive (Loeb 1998)
because although both represent direct mea-
sures of renal function, increases in the
serum concentration of these markers are
generally observed only after frank renal
damage. Consequently, there has been an
ongoing interest in developing new, early
biomarkers of renal damage (Duan et al.
1999;Taylor et al. 1997). The lysosomal
enzyme N-acetylglucosaminidase (NAG) and
the brush border enzyme γ-glutamyl-
transpeptidase (GGT) have also been used to
assess renal toxicity [c.f. Gibey et al. (1981)
and Scherberich and Mondorf (1983)].
When tubules are damaged, NAG and GGT
are excreted into the lumen of the tubules
and can be detected in the urine. However, a
limiting factor in the use of these enzymes,
particularly NAG, is the considerable intra-
and inter-individual variation in urinary
enzyme activity (Naidu and Lee 1994).
Consequently, 24-hour urine collection must
be obtained to allow for diurnal variation of
excretion and urine volume. Recently, uri-
nary levels of speciﬁc isoforms of glutathione
S-transferase have been proposed as topo-
graphically speciﬁc markers of renal damage
(Kilty et al. 1998).
Integratation of emerging transcription
proﬁling technologies into traditional safety
assessment evaluations offers the possibility
to take new steps toward understanding
mechanism of target organ toxicity and elu-
cidating putative new biomarkers of expo-
sure/safety. In 1999 the International Life
Sciences Institute’s (ILSI) Health and
Environmental Sciences Institute (HESI)
chartered a Committee to address this con-
cept. Members of the HESI Genomics
Committee formed a working group
focused on nephrotoxicity. The objective of
the experimental work performed by the
Nephrotoxicity Working Group was to
establish the transcriptional proﬁles of three
mechanistically and topographically distinct
nephrotoxins: cisplatin, gentamicin, and
puromycin. The experiments were also
designed to address biological, technical,
and methodological variability; to evaluate
different approaches to data analysis; and to
understand the application of the technol-
ogy to other proﬁling methodologies and to
mechanism-based risk assessment. The rela-
tionship between changes in renal gene
expression induced by cisplatin, gentamicin,
and puromycin with conventional toxicol-
ogy end points, lesion topography and
potential mediators of mechanism of toxic-
ity was also evaluated and are also discussed
elsewhere in this mini-monograph (Amin
et al. 2004; Thompson et al. 2004).
Experimental Overview
Three nephrotoxicants were selected for
study in male Sprague-Dawley rats, cis-
platin, gentamicin, and puromycin (Amin
et al. 2004). Cisplatin is an antineoplastic
agent used in the treatment of a variety of
solid tumors, although its use is limited
because of severe renal toxicity. Cisplatin is
metabolized to cytotoxic intermediates by
S3 proximal tubular epithelial cells and
induces severe tubular and mild glomerular
toxicity (Dobyan et al. 1980). Gentamicin
is an antibacterial agent of the aminoglyco-
side class. It mediates renal toxicity via
inhibition of proximal tubular epithelial
cell lysosomal function, producing phos-
pholipidosis and tubular degeneration
(Vera-Roman et al. 1975). Puromycin is an
aminonucleoside antibiotic with activity
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Microarrays allow for the simultaneous measurement of changes in the levels of thousands of
messenger RNAs within a single experiment. As such, the potential for the application of transcrip-
tion proﬁling to preclinical safety assessment and mechanism-based risk assessment is profound.
However, several practical and technical challenges remain. Among these are nomenclature issues,
platform-speciﬁc data formats, and the lack of uniform analysis methods and tools. Experiments
were designed to address biological, technical, and methodological variability, to evaluate different
approaches to data analysis, and to understand the application of the technology to other proﬁling
methodologies and to mechanism-based risk assessment. These goals were addressed using experi-
mental information derived from analysis of the biological response to three mechanistically dis-
tinct nephrotoxins: cisplatin, gentamicin, and puromycin aminonucleoside. In spite of the
technical challenges, the transcription proﬁling data yielded mechanistically and topographically
valuable information. The analyses detailed in the articles from the Nephrotoxicity Working
Group of the International Life Sciences Institute Health and Environmental Sciences Institute
suggest at least equal sensitivity of microarray technology compared to traditional end points.
Additionally, microarray analysis of these prototypical nephrotoxicants provided an opportunity
for the development of candidate bridging biomarkers of nephrotoxicity. The potential future
extension of these applications for risk assessment is also discussed. Key words: cisplatin, gentam-
icin, nephrotoxicity, puromycin, risk assessment. Environ Health Perspect 112:460–464 (2004).
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cause necrosis of glomerular podocytes,
resulting in a severe glomerulopathy
(Grond et al. 1988). Severe proteinuria
results from the loss of the glomerular bar-
rier to protein ﬁltration, and tubular injury
occurs secondary to the formation of pro-
teinaceous casts in the proximal tubules.
A preliminary, in vivo study was
conducted in rats exposed to a single toxic
dose of cisplatin to determine the technical
parameters for tissue and RNA isolation and
to direct the design of the overall project.
The single time point (7 days) and dose level
(5 mg/kg) served as a biological replicate for
a subsequent in vivo study with cisplatin.
After an evaluation of this preliminary work,
three in vivo studies were conducted accord-
ing to the design summarized below. The
dose selection was intended to provide infor-
mation relating to no- or minimal-effect
exposures (low), mild effects (mid), and pro-
nounced toxicity (high). In general, five
male rats were necropsied per time point
and dose level. Serum and urine were col-
lected for routine analyses to confirm
nephrotoxicity. Kidneys were snap frozen in
liquid nitrogen for RNA isolation. In gen-
eral, RNA was isolated in a single laboratory
for each study and distributed to participat-
ing laboratories for molecular analysis.
Sections of each kidney were collected in
10% buffered formalin for histologic analy-
sis (hematoxylin and eosin staining).
Additional samples were frozen for potential
proteomic or metabonomic analyses.
Microarray analyses were performed on
oligonucleotide (Affymetrix; http://www.
affymetrix.com) and cDNA-based plat-
forms [PHASE-I (PHASE-1 Molecular
Toxicology, Inc., Santa Fe, NM), NIEHS
(National Institute of Environmental Health
Sciences, Research Triangle Park, NC), and
Incyte Corp. (Palo Alto, CA)] at several par-
ticipant’s home institutions (Table 1). The
complete data set is currently being submit-
ted to ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/) and will be made available on
the HESI website (http://hesi.ilsi.org/
index.cfm?pubentityid=120). Selected tran-
scription profiling results were confirmed
using reverse transcription–polymerase
chain reaction, Western blot analysis, and/or
immunohistochemistry. Administration of
each of the three agents produced the antici-
pated pathologic outcomes as conﬁrmed by
histologic or ultrastructural examination and
evaluation of clinical pathology parameters
(data not shown). Principal component
analyses of both transcription profiling
(Amin et al. 2004) and metabolomic data
(Naciff et al., unpublished results) con-
ﬁrmed distinct expression or metabolite pat-
terns for each nephrotoxicant, with an
apparent closer similarity between cisplatin
and gentamicin. In general, transcriptional
analyses yielded information that provided
strong topographic speciﬁcity and mechanis-
tic information. This conclusion was not
obscured by the considerable intra- and
cross-platform variation. A more detailed
overview of experimental design and key
learnings from the nephrotoxicity working
group are detailed below, and in two articles
in this mini-monograph (Amin et al. 2004;
Thompson et al. 2004).
Analysis of Platform Variability
In this issue, Thompson et al. (2004)
discuss some of the technical and practical
issues associated with interpreting data
from multiple microarray platforms using
data generated from the cisplatin studies.
Comparison of gene expression data from
four microarray platforms of individual and
pooled samples, from identically dosed rats,
and from two separate in vivo experiments
provided a unique opportunity to investi-
gate and evaluate the performance of the
transcription profiling technology com-
pared with more traditional methods of
assessing toxicity.
This experimental design allowed for the
investigation of numerous sources of vari-
ability, including platform technology,
scanner setting, RNA isolation methods,
animal variability, and different sites for
in vivo study completion, RNA isolation,
probe generation, and array hybridization.
Of these, variability due to differences in plat-
form technology was perhaps the most difﬁ-
cult to manage. Comparing single-channel
with dual-channel data, particularly in light
of issues and errors with nomenclature and
the lack of availability of full sequence infor-
mation for some platforms, was problem-
atic. In this mini-monograph, Mattes et al.
(2004) addressed this issue by developing an
approach to uniformly “re-annotate”
microarray elements using UniGene and
LocusLink IDs. A key ﬁnding in this analy-
sis was animal variability, which demon-
strated the pitfalls associated with pooling
biological samples. In cisplatin-induced toxi-
city, a high degree of inter-animal variability
was determined by assessing histologic and
serum chemical parameters. For example,
within the high-dose, late time-point group,
one of the animals was a “low responder,”
and one was essentially a “nonresponder”
relative to the other three responding ani-
mals in the group. In this example, the fre-
quency of individual animal transcript
changes was reduced in low and nonrespon-
ders and increased with more severe toxicity.
As blood levels of the compound were not
measured, we could not definitively deter-
mine whether the variable response was due
to differences in dosing or to variability in
individual animal susceptibility to the toxic
effects of the compound. Regardless, this
analysis suggests that information may be
lost by pooling samples in studies in which
intra-animal variably in response is
observed. This effect was accentuated at
low-dose and/or early time points. 
Mechanistic and Topographic
Information
Amin et al. (2004) in this issue describe the
application of transcription proﬁling for the
identiﬁcation of candidate molecular mark-
ers of kidney toxicity. The data set from
studies with all three nephrotoxicants was
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Table 1. Distribution of participants and compounds analyzed on different technical platforms in the HESI Hepatotoxicity Working Group.
Compound tested: Cisplatin Compound tested: Gentamicin Compound tested: Puromycin
Organization Gene array Organization  Gene array Organization  Gene array
running analysis platform used running analysis platform used running analysis platform used
U.S. FDA PHASE-1 ToxArray 700 Novartis Pharmaceuticals Corp. Affymetrix U34A NIEHS NIEHS custom chip
NIEHS NIEHS custom chip AstraZeneca Affymetrix U34A U.S. FDA PHASE-1 ToxArray 700
Pharmaciaa Incyte Rat GEM1 Wyeth-Ayerst Research Affymetrix U34A
AstraZeneca Affymetrix U34A Pﬁzer Inc Affymetrix U34A
Pﬁzer Inc Affymetrix U34A Amgen Inc. PHASE-1 ToxArray 700
GlaxoSmithKline Custom chip
NIEHS NIEHS custom chip
Pharmaciaa Incyte Rat GEM1 and 3
U.S. FDA PHASE-1 ToxArray 700
Abbreviations: NIEHS, National Institute of Environmental Health Sciences; U.S. FDA, U.S. Food and Drug Administration. 
aNow Pﬁzer Inc. generated on the NIEHS cDNA microarray
platform. For this reason, and to avoid
potential nomenclature and platform-spe-
ciﬁc technical issues, Amin and co-workers
focused on results from the NIEHS rat
array, which contains > 7,000 polymerase
chain reaction–ampliﬁed and sequence-veri-
fied cDNA elements (Hamadeh et al.
2002). These analyses provided both mech-
anistically and topographically interesting
information. Mapping individual genes
whose expression was affected by the
nephrotoxicants into biochemical pathways
provided molecular insights into the nature
of the observed toxicity and of the affected
cell’s efforts to accommodate those effects.
For example, a reduction in the levels of
several mRNAs encoding proteins involved
in the formation of creatinine from L-argi-
nine (Figure 1) was observed on treatment
with a dose of cisplatin that caused aberrant
renal pathology. Creatinine levels in serum
can be used as an indicator of glomerular
ﬁltration rate but are not particularly sensi-
tive to the early stages of renal toxicity. In
the current study, the gene encoding L-argi-
nine-glycine amidinotransferase, a member
of the creatinine biosynthesis pathway, was
affected as early as the ﬁrst day after treat-
ment with cisplatin. Repression of this
pathway may reﬂect an adaptive response to
increased serum creatinine levels due to
reduced glomerular ﬁltration rate resulting
from toxicity to the proximal tubule. 
Work performed by the Nephrotoxicity
Working Group demonstrated a number of
topographically specific gene expression
changes, including changes in a group of
proximal tubule–expressed genes mediated
by cisplatin and gentamicin, which pro-
vided a mechanistic insight into the topo-
graphically distinct nephrotoxicity induced
by these chemicals. An additional example
of the value and robustness of the technol-
ogy was evident on evaluation of the proﬁl-
ing results with puromycin (Amin et al.
2004). Evidence for a mild secondary tubu-
lar lesion was detected on analysis of the
transcription profiling results, which
demonstrated changes in the expression of
several proximal tubule associated tran-
scripts. Although this effect had not been
noticed on initial histopathological evalua-
tion, the finding was confirmed on re-
evaluation in light of the transcription
proﬁling data. 
Finally, the work performed by the
Nephrotoxicity Working Group identified
several potential protein biomarkers.
Although molecular markers of toxicity
may be useful for providing mechanistic
details, protein and metabolite markers
have greater use as noninvasive biomarkers
of intoxication and may translate to the
clinic. As detailed by Amin et al. (2004),
several particularly interesting gene expres-
sion changes could warrant further investi-
gation as candidate protein biomarkers.
In particular, kidney injury molecule-1
(KIM)-1, clusterin, and others may prove
useful as kidney region-specific urinary
protein markers of nephrotoxicity.
Potential Application to Risk
Assessment
A primary objective of the HESI Technical
Committee on the Application of
Genomics to Mechanism Based Risk
Assessment has been to evaluate the appli-
cation of genomics for mechanism-based
preclinical risk assessment. This issue
engendered much discussion at the recent
HESI plenary meeting (held 5–6 June 2003
in Fairfax, Virginia, USA; meeting notes are
available at http://www.ilsi.org/index.
cfm?pubentityid=120) discussed in this
mini-monograph by Pennie et al. (2004).
However, the relatively limited studies
completed to date are insufﬁcient to address
risk assessment. Although topographical
and mechanistic information was obtained
from the experiments performed by the
Nephrotoxicity Working Group, expression
profiling in a single tissue and a single
species cannot be construed as risk assess-
ment. Additionally, in the absence of
in vivo efﬁcacy measurements, no therapeu-
tic indices could be determined for any of
these studies. Finally, the likely error rates
associated with microarray technology are
such that it would be difﬁcult to know how
to use or interpret the data without validat-
ing each individual result. On a microarray
with 10,000 elements, even a 1% error rate
corresponds to 100 false results. To address
this uncertainty, scientists in the nephrotox-
icity and other working groups used path-
way mapping to identify biochemical
pathways that were affected upon treatment
with a toxicant. However many biochemi-
cal pathways are underrepresented on
microarrays or have only a few members
that are transcriptionally regulated. In addi-
tion, a large number (> 50%) of signifi-
cantly changed genes were expressed
sequence tags that have not yet been func-
tionally defined. Therefore, in spite of the
useful information that may be gleaned
from a microarray experiment, current
methodologies in pathway mapping may
not be directly applicable to an assessment
of risk at this time.
For the reasons described above, there
is significant concern about the misinter-
pretation of the significance of individual
gene or pathway-speciﬁc events observed in
microarray data beyond general mechanis-
tic interpretation. Presently, there is a lack
of understanding of the context of a gene
expression change. For example, changes
may be related to pharmacology, metabo-
lism, adaptive, or pathology end points.
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Figure 1. The creatinine biosynthesis pathway is necessary for the formation of creatinine from L-arginine.
ADP, adenosine diphosphate; ATP, adenosine triphosphate. Creatinine levels in serum can be used as an
indicator of glomerular ﬁltration rate, but are not particularly sensitive to the early stages of renal toxicity.
According to  Amin et al. (2004), L-arginine-glycine amidinotransferase and guanidinoacetate methyltrans-
ferase were repressed as early as the ﬁrst day after treatment with cisplatin.For example, in a metabolically active
organ such as the liver, it may be impossi-
ble to observe a no-effect level on gene
expression. In such a tissue, the smallest
measurable amount of a biologically active
compound would likely result in changes
in the expression of genes encoding metab-
olism and clearance proteins, even in the
complete absence of any toxicological
responses. Similarly, in a drug target tissue,
efﬁcacy is just as likely as toxicity to result
in gene expression changes. Until the com-
plete function and interactivity of every
gene product and every biochemical path-
way is known, it would be impossible to
distinguish a no-effect from a no-adverse
effect level. Therefore, because of these
limitations, application of profiling tech-
nologies is not currently being applied rou-
tinely in regulatory studies.
How to address some of these concerns
may have been resolved at the recent HESI
plenary meeting. Specifically, many con-
tributors to the HESI consortium used
principal component analysis to distinguish
groups on the basis of dose, mechanism,
and lesion topography. In some examples,
the lowest-dose groups were indistinguish-
able from the controls (or, in the case of
2-channel array data, low dose vs. control
was indistinguishable from control vs. con-
trol hybridizations). In such cases, the fact
that evaluation of the expression level of
hundreds or thousands of individual tran-
scripts cannot distinguish between a treated
and an untreated animal supports an
absence of toxicity, regardless of the iden-
tity and function of the genes and path-
ways themselves. Figure 2 shows such an
example, wherein the transcription profile
of mid- and high-dose–group animals
treated with a pancreatic toxicant are
clearly separated from the control vs. con-
trol hybridizations. In this example, the
first principle component clearly distin-
guishes toxic from non- or pretoxic out-
comes. The profile of the lowest-dose
group, from a dose level in which no
histopathological evidence for toxicity was
observed, was indistinguishable from the
control versus control hybridizations. In
the extremely high-order theoretical space
used in such analyses, a small number
of nonsystematic errors in individual
hybridizations would be unlikely to cause
an artificial separation of these groups.
Furthermore, the exact function of the
gene products of the affected mRNAs is
largely irrelevant. In cases where efficacy
end points and toxicity were observed in
the same tissue, the use of efficacious and
nonefficacious structural analogs could be
used to distinguish efficacy from pharma-
cophore-mediated toxicity. Similarly,
inclusion of genetically engineered animal
models in toxicogenomic experiments
would also be useful in distinguishing
between pharmacology (both desirable and
adverse) and pharmacophore-mediated tox-
icity. Of course, several caveats must be
placed on such a supposition. For example,
this approach may be valid only in toxicity
target organs that also were not targets for
efﬁcacy and also were not actively involved
in the metabolism and clearance of the
compound.
In an effort to distinguish toxic from
nontoxic compounds, many companies
have developed databases containing the
expression proﬁles of numerous well charac-
terized compounds. They then use pattern
recognition approaches to distinguish
between safe and toxic compounds to pre-
dict toxicological liabilities of novel lead
compounds. However, current pattern
recognition approaches are widely varied
and the field is undergoing rapid develop-
ment. Different databases and approaches
to pattern recognition may yield different
predictions of risk, raising false concerns
over compounds in the absence of any evi-
dence of toxicity. For this reason, pattern
recognition is perhaps not ready for regula-
tory risk assessment. Development of cus-
tom medium density methodologies has
gained some popularity as a potential means
of querying a subset of well-understood
genes in which the predictive value has been
more fully characterized. Meanwhile, pat-
tern recognition approaches applied to
large-scale profiling data sets can allow for
an internal assessment of the conﬁdence in
safety of an early lead compound.
Commentary
Toxicity studies in rats reproduced the
topographically and mechanistically distinct
renal lesions associated with administration
of cisplatin, gentamicin, and puromycin.
The time–course and dose–response rela-
tionships of these agents was appropriate for
further study of transcriptional regulation.
Our analyses suggest at least equal sensitiv-
ity of microarray technology compared to
traditional end points and yielded topo-
graphically and mechanistically inter-
pretable information. Microarray analysis of
nephrotoxicants provides an avenue for
development of biomarkers and for gaining
additional insight into toxicologic mecha-
nism of action. Overall, the toxicogenomic
evaluation of nephrotoxicants has demon-
strated potential in enhancing risk assess-
ment through providing mechanistic
information relating to the pathogenesis
of toxicity.
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